Glyburide inhibits the Cryopyrin/Nalp3 inflammasome

By M. Lamkanfi, James L. Mueller, Alberto C. Vitari, S. Misaghi, A. Fedorova, K. Deshayes, Wyne P. Lee, H. Hoffman, V. Dixit. Journal of Cell Biology, 2009

816 citations recorded by the source corpus.

Glyburide, a sulfonylurea drug commonly used to treat type 2 diabetes, shuts down IL-1β secretion by preventing Cyropyrin activation.

Subfields: Molecular Biology, Nephrology

View Paper: https://www.semanticscholar.org/paper/5a0031e9f4651f09cceb85fe8ae046b1cd31b1ad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Lamkanfi
2. Katherine A. Fitzgerald
3. J. Tschopp
4. Greta Guarda
5. O. Gross
6. G. van Loo
7. Christina J. Thomas
8. D. Underhill

In Nephrology

1. J. Tschopp

Citations in the corpus

• Inflammasomes in neuroinflammatory and neurodegenerative diseases (2019, background): “RP-1127, an intravenous formulation of the NLRP3 inflammasome inhibitor glyburide (Lamkanfi et al, 2009), is being tested in a clinical trial for stroke (EudraCT 2017-004854-41) after a positively evaluated pilot study (ClinicalTrials.gov: NCT01268683) (Sheth et al, 2014).”
• Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. (2012, background): “Low intracellular K+ has been linked to caspase-1 activation by the NLRP3 inflammasome (Lamkanfi et al., 2009; Pétrilli et al., 2007).”
• The inflammasome: an integrated view (2011, background): “Furthermore, inflammasome activation in response to many NLRP3 activators is effectively inhibited, by the potassium channel inhibitor glibenclamide (83).”